Navigation Links
Luminex and One Lambda Renew Long-Term Strategic Partnership
Date:12/7/2010

AUSTIN, Texas, Dec. 7, 2010 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX) and One Lambda, Inc., the leading producer of transplant diagnostic products, have agreed to a long-term renewal of their 10-year strategic partnership aimed at developing platforms and technologies for human leukocyte antigen (HLA) typing and antibody screening for the organ transplantation market. Begun in 2000, their dedicated collaboration has resulted in the creation of innovative products that have made pre- and post-transplant diagnostics faster, and more cost-efficient.

(Logo:  http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

"One Lambda and Luminex combined the power of Luminex's xMAP® Technology with One Lambda's expertise in HLA testing and organ transplantation to dramatically advance the care available to those undergoing transplants," said George Ayoub, president and CEO of One Lambda. "Our platforms have significantly enhanced healthcare providers' ability to care for organ transplant patients by delivering vital information that helps them to better match donors with recipients."

Effective diagnostics are essential in transplant medicine. HLA typing and antibody screening are critical in matching organ donors and organ recipients, minimizing rejection and maintaining transplant patients' long-term health following a transplant. This kind of testing can require screening a patient for hundreds of HLA markers and antibodies. One Lambda's dedication to innovation ensures their products are continually updated with the latest donor registry data and new DNA genotypes. The simplicity and flexibility of the xMAP Technology platform to analyze both nucleic acids and proteins has allowed One Lambda to enhance and expand their product menu.

"Luminex and One Lambda have set the standard for strategic partnership with our collaboration that has delivered new technology and transformed the practice of transplantation medicine," said Patrick J. Balthrop, president and CEO of Luminex. "One Lambda has an impressive history of innovation in the field of transplantation, and we expect that our work together will continue to deliver significant technology advances and market leadership into the next decade."

One Lambda adopted Luminex's xMAP Technology to create products that could reduce the cost and complexity of HLA typing and antibody screening. The xMAP platform, which allows multiple, simultaneous tests to be run on a single sample, proved to be an ideal fit for transplant testing. The flexible technology helped One Lambda to develop a range of assays that have streamlined transplant diagnostics. One Lambda's LABType® SSO and LABScreen® products can detect up to 500 HLA specificities in a single test, eliminating the need to run multiple tests. One Lambda's xMAP-based assays are used in more than 80 countries worldwide.

About One LambdaOne Lambda, Inc. is the worldwide leader in HLA typing and antibody detection assays. One Lambda is known for its commitment to quality, service, and innovation. One Lambda develops and distributes several lines of HLA typing and antibody detection tests utilizing serological, molecular, ELISA, flow, and Luminex xMAP technologies. One Lambda also manufactures laboratory instrumentation and computer software that are used to simplify and automate testing procedures and final test evaluations. For more information, please visit www.onelambda.com.

About Luminex CorporationLuminex Corporation develops, manufactures, and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate, and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics, and biomedical research, including the genomics and proteomics markets. The company's xMAP Technology is sold worldwide and is already in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.Contacts:One Lambda:James Keegan, 818.702.0042Chief Financial OfficerLuminex Investor Contact:Matthew Scalo, 512.219.8020  Sr. Director Investor Relations  mscalo@luminexcorp.comLuminex Media Contact: Mimi Torrington, 512.219.8020Director of Marketing Communicationsmtorrington@luminexcorp.comAaron DeLucia, 512.241.2249  aaron.delucia@porternovelli.com
'/>"/>

SOURCE Luminex Corporation; One Lambda, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation Board of Directors Authorizes Share Repurchase Plan Through November 2011
2. Luminex Corporation Launches New FDA Cleared Pharmacogenetic Diagnostic Test
3. Luminex Corporation to Present at Stephens Fall Investment Conference
4. Luminex Corporation Reports Third Quarter 2010 Results
5. Luminex Corporation Third Quarter Earnings Release Scheduled for November 4, 2010
6. Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna
7. Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution
8. Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award
9. Luminex to Host MAGPIX Road Shows Throughout the U.S. and Europe
10. Luminex Corporation to Present at UBS Global Life Sciences Conference
11. Luminex MAGPIX System Shown to be More Cost Effective and Efficient Than Conventional ELISA Method in Initial Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Feb. 9, 2016 The new report "Global Anti-Bacterial Drugs ... Research & Consulting group reveals that the North America ... share of 38.9% in 2014 that translated into revenues worth US$ ... Europe , Asia-Pacific , ... Africa . The global anti-bacterial market is inclined towards ...
(Date:2/8/2016)... LONDON , Feb.8, 2016 Alzheimer ... Summary Medical Devices sector report ... Assessment, 2015" provides an overview of Alzheimer Diagnostic ... provides comprehensive information on the pipeline products with ... of development. The report reviews major players involved ...
(Date:2/8/2016)... 2016  Labvantage Lx, a newcomer to the ... sexual enhancement product, EnduramenT. Setting a new standard ... a patented biomedical breakthrough molecule that promotes the ... responsible for many biological functions including erectile function. ... Forgoing the use of prescription medications, scientists working ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 10, 2016 , ... The Journal of Pain Research has ... field .” , As corresponding author Dr John F. Peppin says “Terminology matters, yet ... our chronic pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... service to expand access to affordable hearing aids , increase industry transparency, ... individuals in the United States. , “For the average consumer, the hearing aid ...
(Date:2/9/2016)... ... , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter Lockley ... 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of the ... 2015, the Maui Photo Expedition workshop will once again consist of on-location ...
(Date:2/9/2016)... California (PRWEB) , ... February 09, 2016 , ... i2i ... one of the highest preliminary data vendors in the latest KLAS report, Population Health ... i2i has led the developing market for population health management (PHM). The latest ...
(Date:2/8/2016)... N.J. (PRWEB) , ... February 08, 2016 , ... ... cancer patients, has officially launched the Multiple Myeloma Heroes Awards event , which ... or in the lives of patients with MM. The MM Heroes Awards nomination ...
Breaking Medicine News(10 mins):